Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Cyclic nucleotide specific phosphodiesterases as potential drug targets for anti-Leishmania therapy.

Sebastián-Pérez V, Hendrickx S, Munday JC, Kalejaiye T, Martínez A, Campillo NE, de Koning H, Caljon G, Maes L, Gil C.

Antimicrob Agents Chemother. 2018 Aug 13. pii: AAC.00603-18. doi: 10.1128/AAC.00603-18. [Epub ahead of print]

PMID:
30104270
2.

Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model.

Arrospide A, Idigoras I, Mar J, de Koning H, van der Meulen M, Soto-Gordoa M, Martinez-Llorente JM, Portillo I, Arana-Arri E, Ibarrondo O, Lansdorp-Vogelaar I.

BMC Cancer. 2018 Apr 25;18(1):464. doi: 10.1186/s12885-018-4362-1.

3.

European position statement on lung cancer screening.

Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel CP, Bastarrika G, Sverzellati N, Mascalchi M, Delorme S, Baldwin DR, Callister ME, Becker N, Heuvelmans MA, Rzyman W, Infante MV, Pastorino U, Pedersen JH, Paci E, Duffy SW, de Koning H, Field JK.

Lancet Oncol. 2017 Dec;18(12):e754-e766. doi: 10.1016/S1470-2045(17)30861-6. Review.

PMID:
29208441
4.

Risk stratification based on screening history: the NELSON lung cancer screening study.

Yousaf-Khan U, van der Aalst C, de Jong PA, Heuvelmans M, Scholten E, Walter J, Nackaerts K, Groen H, Vliegenthart R, Ten Haaf K, Oudkerk M, de Koning H.

Thorax. 2017 Sep;72(9):819-824. doi: 10.1136/thoraxjnl-2016-209892. Epub 2017 Mar 30.

PMID:
28360223
5.

Multiethnic Exome-Wide Association Study of Subclinical Atherosclerosis.

Natarajan P, Bis JC, Bielak LF, Cox AJ, Dörr M, Feitosa MF, Franceschini N, Guo X, Hwang SJ, Isaacs A, Jhun MA, Kavousi M, Li-Gao R, Lyytikäinen LP, Marioni RE, Schminke U, Stitziel NO, Tada H, van Setten J, Smith AV, Vojinovic D, Yanek LR, Yao J, Yerges-Armstrong LM, Amin N, Baber U, Borecki IB, Carr JJ, Chen YI, Cupples LA, de Jong PA, de Koning H, de Vos BD, Demirkan A, Fuster V, Franco OH, Goodarzi MO, Harris TB, Heckbert SR, Heiss G, Hoffmann U, Hofman A, Išgum I, Jukema JW, Kähönen M, Kardia SL, Kral BG, Launer LJ, Massaro J, Mehran R, Mitchell BD, Mosley TH Jr, de Mutsert R, Newman AB, Nguyen KD, North KE, O'Connell JR, Oudkerk M, Pankow JS, Peloso GM, Post W, Province MA, Raffield LM, Raitakari OT, Reilly DF, Rivadeneira F, Rosendaal F, Sartori S, Taylor KD, Teumer A, Trompet S, Turner ST, Uitterlinden AG, Vaidya D, van der Lugt A, Völker U, Wardlaw JM, Wassel CL, Weiss S, Wojczynski MK, Becker DM, Becker LC, Boerwinkle E, Bowden DW, Deary IJ, Dehghan A, Felix SB, Gudnason V, Lehtimäki T, Mathias R, Mook-Kanamori DO, Psaty BM, Rader DJ, Rotter JI, Wilson JG, van Duijn CM, Völzke H, Kathiresan S, Peyser PA, O'Donnell CJ; CHARGE Consortium.

Circ Cardiovasc Genet. 2016 Dec;9(6):511-520. doi: 10.1161/CIRCGENETICS.116.001572. Epub 2016 Nov 21.

6.

Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval.

Yousaf-Khan U, van der Aalst C, de Jong PA, Heuvelmans M, Scholten E, Lammers JW, van Ooijen P, Nackaerts K, Weenink C, Groen H, Vliegenthart R, Ten Haaf K, Oudkerk M, de Koning H.

Thorax. 2017 Jan;72(1):48-56. doi: 10.1136/thoraxjnl-2016-208655. Epub 2016 Jun 30.

PMID:
27364640
7.

Strapping rowers to their sliding seat improves performance during the start of single-scull rowing.

van Soest AJ, de Koning H, Hofmijster MJ.

J Sports Sci. 2016 Sep;34(17):1643-9. doi: 10.1080/02640414.2015.1130235. Epub 2016 Jan 13.

PMID:
26758804
8.

Baseline Characteristics and Mortality Outcomes of Control Group Participants and Eligible Non-Responders in the NELSON Lung Cancer Screening Study.

Yousaf-Khan U, Horeweg N, van der Aalst C, Ten Haaf K, Oudkerk M, de Koning H.

J Thorac Oncol. 2015 May;10(5):747-53. doi: 10.1097/JTO.0000000000000488.

9.

The importance of screening for lung cancer.

Horeweg N, de Koning H.

Expert Rev Respir Med. 2014 Oct;8(5):597-614. doi: 10.1586/17476348.2014.937428. Epub 2014 Aug 27. Review.

PMID:
25158921
10.

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H.

BMC Med. 2014 Feb 11;12:26. doi: 10.1186/1741-7015-12-26.

11.

Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention.

Mandelblatt J, van Ravesteyn N, Schechter C, Chang Y, Huang AT, Near AM, de Koning H, Jemal A.

Cancer. 2013 Jul 15;119(14):2541-8. doi: 10.1002/cncr.28087. Epub 2013 Apr 26.

12.

Genome-wide association study of coronary and aortic calcification implicates risk loci for coronary artery disease and myocardial infarction.

van Setten J, Isgum I, Smolonska J, Ripke S, de Jong PA, Oudkerk M, de Koning H, Lammers JW, Zanen P, Groen HJ, Boezen HM, Postma DS, Wijmenga C, Viergever MA, Mali WP, de Bakker PI.

Atherosclerosis. 2013 Jun;228(2):400-5. doi: 10.1016/j.atherosclerosis.2013.02.039. Epub 2013 Mar 13.

13.

Schnitzler's syndrome: diagnosis, treatment, and follow-up.

Simon A, Asli B, Braun-Falco M, De Koning H, Fermand JP, Grattan C, Krause K, Lachmann H, Lenormand C, Martinez-Taboada V, Maurer M, Peters M, Rizzi R, Rongioletti F, Ruzicka T, Schnitzler L, Schubert B, Sibilia J, Lipsker D.

Allergy. 2013;68(5):562-8. doi: 10.1111/all.12129. Epub 2013 Mar 9. Review.

PMID:
23480774
14.

Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review.

Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, Paci E; EUROSCREEN Working Group.

J Med Screen. 2012;19 Suppl 1:42-56. Review.

PMID:
22972810
15.

Do women make an informed choice about participating in breast cancer screening? A survey among women invited for a first mammography screening examination.

van Agt H, Fracheboud J, van der Steen A, de Koning H.

Patient Educ Couns. 2012 Nov;89(2):353-9. doi: 10.1016/j.pec.2012.08.003. Epub 2012 Sep 7.

PMID:
22963769
16.

Informing on prenatal screening for Down syndrome prior to conception. An empirical and ethical perspective.

Schoonen M, van der Zee B, Wildschut H, de Beaufort I, de Wert G, de Koning H, Essink-Bot ML, Steegers E.

Am J Med Genet A. 2012 Mar;158A(3):485-97. doi: 10.1002/ajmg.a.35213. Epub 2012 Feb 2.

PMID:
22302760
17.

Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.

van Leeuwen PJ, Otto SJ, Kranse R, Roobol MJ, Bul M, Zhu X, de Koning H, Schröder FH.

BJU Int. 2012 Jul;110(2):188-94. doi: 10.1111/j.1464-410X.2011.10811.x. Epub 2012 Jan 30.

18.

No benefit for consensus double reading at baseline screening for lung cancer with the use of semiautomated volumetry software.

Wang Y, van Klaveren RJ, de Bock GH, Zhao Y, Vernhout R, Leusveld A, Scholten E, Verschakelen J, Mali W, de Koning H, Oudkerk M.

Radiology. 2012 Jan;262(1):320-6. doi: 10.1148/radiol.11102289. Epub 2011 Nov 21.

PMID:
22106357
19.

The provision of information and informed decision-making on prenatal screening for Down syndrome: a questionnaire- and register-based survey in a non-selected population.

Schoonen M, Wildschut H, Essink-Bot ML, Peters I, Steegers E, de Koning H.

Patient Educ Couns. 2012 Jun;87(3):351-9. doi: 10.1016/j.pec.2011.10.001. Epub 2011 Oct 24.

PMID:
22030253
20.

Lead-time in the European Randomised Study of Screening for Prostate Cancer.

Finne P, Fallah M, Hakama M, Ciatto S, Hugosson J, de Koning H, Moss S, Nelen V, Auvinen A.

Eur J Cancer. 2010 Nov;46(17):3102-8. doi: 10.1016/j.ejca.2010.09.034.

PMID:
21047593

Supplemental Content

Loading ...
Support Center